Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

NCT05564806 | Recruiting Phase 1

• 1 other identifier: YH004003
• Study Type: interventional
• Target: 38
• Locations: 1 country
• Sites: 2

Brief Summary

This is an multicenter, open-label, dose-escalation study of the study drug YH004 . The study is designed to determine the safety, tolerability, maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of YH004 in subjects with advanced solid tumors and relapsed or refractory Non-Hodgkin lymphoma.

Conditions

Advanced Solid Tumors; Relapsed Or Refractory Non-Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (2)

• Adverse events (AEs)

  The safety profile of YH004 will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0.

  up to 1 year after the last dosing

• Maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D)

  The MTD and/or RP2D will be determined based on the data of safety and tolerability.

  up to 1 year after the last dosing

Study Arms (1)

Intervention/treatment

EXPERIMENTAL

All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.

Drug: YH004

Interventions

YH004 DRUG

All subject will receive YH004 intravenously as single agent every three weeks (Q3W), until intolerable toxicity, disease progression, withdrawal of consent, or Investigator decision, whichever comes first.

Intervention/treatment

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willing and able to provide signed and dated informed consent prior to any study related procedures and willing and able to comply with all study procedures.
• Patients with histologically or cytologically confirmed advanced solid tumor or relapsed or refractory Non-Hodgkin Lymphoma (including but not limited to inert and transformed type, patients with inert lymphoma must undergo systematic treatment at the time of screening), which has progressed after treatment with standard therapies or intolerant of standard therapies or have no standard of care.
• Subject must have at least one measurable lesion by RECIST 1.1 or per Cheson criteria (Lugano 2014).
• Subjects must be 18 years to 80 years of age at the time of screening.
• Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Have life expectancy of at least 12 weeks based on investigator's judgement.
• Sufficient organ and bone marrow functions before screening or administration.
• Women of reproductive potential must have negative serum beta human chorionic gonadotropin (β -HCG) pregnancy test at the time of screening.
• Women of reproductive potential who are sexually active must consistently use highly effective contraception/birth control (less than 1% per year) between signing of the informed consent and 90 days after the last administration of the study drug.

You may not qualify if:

• Previous exposure to an anti-CD137 (e.g., utomilumab, urelumab) antibodies.
• Subjects must not have another active invasive malignancy within 2 years or currently.
• Subjects have received any anticancer therapy or another investigational agent within the longer of 4 weeks or 5 half-lives before the first dose of the study drug.
• Continuance of toxicities due to prior anti-tumor therapy that have not recovered to ≤ Grade 1 per CTCAE 5.0.
• Subjects who have major operations within 4 weeks before the first dose of the study drug, or minor surgery within 2 weeks prior to the first dose.
• Subjects have received any radiotherapy within the longer of 4 weeks before the first dose of the study drug.
• Subjects with primary CNS malignancy or symptomatic CNS metastasis.
• Subjects with a history of ≥ Grade 3 immune-related adverse events resulted from previous immunotherapy or treatment discontinuation due to previous immunotherapy.
• Subjects must not receive concurrent or prior use of an immunosuppressive agent within 4 weeks of the first dose of study drug.
• Subjects must not receive any other investigational drug or participated in other clinical studies within 4 weeks before the first dose of study drug.
• Subjects must not have received a live vaccine or attenuated live vaccine within 4 weeks before the first dose of study drug.
• Known allergies to the active ingredient or excipients of the test drug, or history of severe allergic reaction (≥ grade 3) to any other monoclonal antibody or intravenous therapeutic protein preparation drug.
• History of interstitial lung disease or noninfectious pneumonia requiring corticosteroid treatment.
• More than moderate amount of uncontrollable pleural, abdominal or pericardial effusion requiring repeated drainage or with obvious symptoms.
• Subjects must not have an active autoimmune disease, a history of autoimmune disease requiring systemic therapy, or a history of autoimmune disease within 2 years of the first dose of study drug.

Sponsors & Collaborators

• Eucure (Beijing) Biopharma Co., Ltd: lead

Study Sites (2)

Henan Cancer Hospital

Zhengzhou, Henan, 450008, China

RECRUITING

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310020, China

RECRUITING

Central Study Contacts

Fangxia Pan

CONTACT

+86 010 85950770; fangxia.pan@eucure.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Clinical trials with a single arm

Study Record Dates

• First Submitted: September 29, 2022
• First Posted: October 4, 2022
• Study Start: January 31, 2023
• Primary Completion: October 24, 2025
• Study Completion: February 7, 2026
• Last Updated: September 7, 2023

Record last verified: 2022-10

Locations

CN (2)